Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. reports developments in its global medical cannabis business, including product launches, brand expansion and regulated-market activity across Canada, Europe, Australia and New Zealand. The company serves medical and consumer cannabis markets through brands such as Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler, with GMP-certified manufacturing facilities in Canada and Germany.
Recurring announcements cover new formats such as dried flower, pre-rolls, pastilles and resin cartridges; operating and financial results; international market engagement; capital actions; and governance updates. Aurora's news also reflects its medical-first strategy and use of a global manufacturing network to supply regulated cannabis markets.
Aurora Cannabis (ACB) announced the repurchase of approximately $102.5 million of its convertible senior notes for $99.4 million in cash, achieving a 4.5% discount. This marks a total repurchase of $316.5 million over the past year, leading to annual cash interest savings of $17.4 million. The company reports a strong balance sheet and aims to achieve Adjusted EBITDA profitability by December 31, 2022.
Aurora Cannabis Inc. (ACB) announced the results of its Annual General and Special Meeting held on November 14, 2022. A total of 92,937,078 shares, or 30.93% of issued shares, were represented. All proposed matters were approved, including the election of directors with high approval rates: Miguel Martin received 92.56% support, and Norma Beauchamp 83.50%. Shareholders also approved KPMG as auditors and amendments to several compensation plans. The voting results report is available on SEDAR.
Aurora Cannabis Inc. (NASDAQ: ACB) will discuss its Q1 fiscal year 2023 results on November 10, 2022, at 5:00 p.m. ET. The Company will announce its financial results after market close on the same day. Aurora continues to carve a niche in the cannabis industry, emphasizing quality and innovation in both medical and consumer markets. The conference call will feature CEO Miguel Martin and CFO Glen Ibbott, providing insights into the Company's financial performance and future outlook.
Aurora Cannabis (NASDAQ: ACB, TSX: ACB) has filed its management information circular in preparation for its annual and special meeting of shareholders on November 14, 2022. The materials, now being mailed to shareholders, outline the business to be discussed, voting instructions, and participation details. Key items for voting include the election of nine directors, the appointment of KPMG LLP as auditors, and amendments to the stock option plan. The Board recommends voting in favor of all proposals.
Aurora Cannabis (NASDAQ: ACB) announced a major fall product launch, expanding its portfolio across adult-use and medical markets. The lineup features innovative strains such as Electric Honeydew and Ultra Grape Kush, showcasing unique genetics and high-potency THC levels. The new products include high-potency gummies, flower, and infused pre-rolls. This marks Aurora's most substantial release in over two years, with over 60 new offerings becoming available in October.
Aurora Cannabis (NASDAQ: ACB, TSX: ACB) announced on October 7, 2022, a repurchase of approximately $31.3 million in convertible senior notes, costing $29.8 million in cash, including interest. This transaction aims to reduce the company's debt and annual cash interest costs, yielding annual savings of about $11.9 million. With roughly $380 million in cash and cash equivalents, Aurora's balance sheet remains robust, and the company expects to achieve a positive Adjusted EBITDA run rate by December 31, 2022.
Akanda prepares for its first export shipment of premium cannabis from its Portugal-based Holigen facility to Germany. The company targets a 10% market share in the growing German medical cannabis sector, backed by a supply agreement with Cansativa for 1,000 kilograms of cannabis. This initiative positions Akanda to capitalize on Germany's medical cannabis market, which has seen a 27% increase in imports. Additionally, Akanda has partnered with Cookies to enhance its brand presence and expand into potential adult-use markets in Europe.
Aurora Cannabis (ACB) announced strong Q4 2022 results, with international medical cannabis net revenue up 35.4% year-over-year and 70.3% from fiscal 2021. The company reaffirmed its adjusted EBITDA profitability run rate by December 31, 2022 and projected $150-170 million in annual cost savings. Aurora strengthened its balance sheet with a $155.3 million debt reduction and made profitable acquisitions, enhancing growth opportunities. Despite challenges in the Canadian market, the firm remains focused on high-margin segments.
Akanda Corp. announced the appointment of Terry Booth, founder of Aurora Cannabis (NASDAQ: ACB), as the Chair of its new Advisory Board, aimed at enhancing the company's European strategy. Booth led Aurora's growth into a $16 billion market cap company and has significant experience in the cannabis sector. Akanda’s CEO, Tej Virk, highlighted Booth's expertise as a validation of their strategy to lead the emerging European cannabis market. Booth expressed confidence in Akanda's positioning within the industry.
Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) announced a conference call on September 20, 2022, at 5:00 p.m. Eastern Time to discuss its fourth quarter and full fiscal year 2022 results, releasing financial data that same day. The CEO, Miguel Martin, and CFO, Glen Ibbott, will lead the discussion, which will be available via webcast. Additionally, Aurora has scheduled its Annual General and Special Meeting of shareholders on November 14, 2022, at 1 p.m. Eastern Time, providing shareholders with further insights into company performance.